Mini-IV Drip Bag Delivery of Vincristine Avoids Risk of Deadly Errors

Article

Delivering vincristine via mini-IV drip bags instead of pushing it with a syringe might avoid injection into spinal fluid, which is uniformly fatal.

Simply diluting and delivering vinca alkaloids like vincristine via mini-IV drip bags instead of pushing these chemotherapy agents with a syringe might avoid accidental injection into spinal fluid, researchers reported in a poster session at the Oncology Nursing Society (ONS) 42nd Annual Congress, held May 4–7 in Denver.

“This was a big change in practice for bedside nurses at Johns Hopkins Hospital who had, to this point, always administered vesicants-other than continuous infused vesicants-as an intravenous push through the side port of a free-flowing line,” reported MiKaela Olsen, MS, APRN-CNS, AOCNS, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, in a statement.

The researchers found that delivering these agents via mini-IV drip is safe in an analysis of patient data that spanned 12 months of clinical experience at Johns Hopkins Hospital. The team found that after more than 1,300 mini-bag vincristine administrations, no cases of extravasation occurred.

The change to a mini-IV drip bag was first adopted for pediatric oncology and involved careful planning by nursing and pharmacy staff, Olsen noted.

Nurses were trained using a video tutorial on the safe mini-bag administration of vincristine to avoid extravasation, before using the new procedure with patients. The video teaches nurses to remain by the patient’s side during the 5-minute vincristine administration procedure, checking blood returns. “This approach was key to our success,” Olsen emphasized.

Not all nurses understood that accidentally administering vincristine to spinal fluid is uniformly fatal for patients, the researchers found. Vincristine should be labeled with a warning reading “For intravenous use only-fatal if given other routes.”

Last year, the National Comprehensive Cancer Network (NCCN) initiated a “Just Bag It!” campaign to promote new guidelines urging the safe dilution and drip administration of vincristine in order to avoid the risk of preventable, fatal clinical errors associated with syringe delivery. It is impossible to accidentally deliver vincristine into spinal fluid if it is delivered by mini-IV drip. Drip delivery also reduces the risk of dosing error, Olsen and her colleagues noted.

NCCN Chief Executive Officer Robert W. Carlson, MD, said that the researchers’ findings were welcome news that he hoped would encourage others to change from syringe to mini-IV drip delivery of vincristine.

“Our staff feel confident that this new procedure is safe and that it is absolutely the right thing to do to prevent patient harm,” Olsen said. “Once we made the change, we did not look back.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content